Dimerix Limited (ASX:DXB) has confirmed it’s begun recruiting adolescent kidney disease patients in Mexico, now that its ‘ACTION3‘ Phase 3 clinical trial location has been selected. Ages range from 12 to 17. HotCopper users were perusing the announcement pre-market trades – the most popular announcement of the day thus far. Dimerix is expanding its scope beyond Mexico, too – the company flagged an additional 14 specialist paediatric clinical sites are set to open in Argentina, the UK and the US. It’s also appointed an expert nephrologist to its board. “I am delighted to be extending my relatio…